Farmanews.com

Notas de Prensa  

Farmacología. 04 de febrero de 2019
M. miralpeix's approach is that of an independentt with over 25 years of experience in drug discovery & early development of drugs

M. Miralpeix Pharma Consulting establishes its headquarters at the Barcelona Science Park

M. Miralpeix Pharma Consulting, specialized in providing scientific and strategic advice to companies and public and private research centres linked to life sciences and healthcare, has opened its headquarters at the Barcelona Science Park. The objective of the consultancy firm is to interact in an ecosystem that enables it to strengthen its links with the main players in the pharmaceutical and biotech sector to boost its R&D&I projects towards a more advanced phase, closer to the market.

Resultat d'imatges de montse miralpeix

M. Miralpeix Pharma Consulting is an independent consultancy firm established in November 2018 by Montse Miralpeix, with a PhD in Biology and more than 25 years of experience in the drug discovery field, in pursuit of projects for licenses in the pharmaceutical and biotechnology industry.

The company is based on the global vision and extensive knowledge of all phases of the discovery and development of drugs that its founder has acquired through directing and supervising more than 30 projects in the inflammation and fibrosis areas, of which eight compounds have reached the clinical phase and two are on the market.

The objective of the consultancy firm is to add value to projects by identifying the most critical needs and activities involved in each stage of the R&D process, in order to shorten decision time and reduce the required resources. Another aspect of M. Miralpeix Pharma Consulting is the research and evaluation of projects to license, as well as the preparation of material for the identification of licensees. One of its most important clients in this field is the Belgian company Galapagos NV (Euronext & NASDAQ: GLPG).

Some of the advisory services that M. Miralpeix Pharma Consulting provides include: how to validate a new mechanism of action for a disease and identify what needs it can cover; how to differentiate from competitors and current treatments; identification of the most appropriate efficacy models; the definition of a screening cascade for each phase of the project, including efficacy, safety, ADME (absorption, distribution, metabolism and excretion) and toxicology assays; mentoring of project leaders; the preparation of confidential and non-confidential information to find partners or licensees; and the search for projects to license.

“M. Miralpeix Pharma Consulting wants to be an independent, honest, committed and motivated consultancy firm. In order to develop our objectives, it is very important to be in an environment that provides us contact with the world of biomedicine, biotechnology and medical technologies, and that allows dynamic interactions with the ecosystem of startups, biotech and public research groups. To be located in the Parc Científic de Barcelona was thus a strategic decision taken by the company”, says Montse Miralpeix, founder and CEO.

 

Subir  

Subir notas de prensa y convocatorias

Próximas convocatorias   

No hay próximas convocatorias
Ver todas

Especialidades  

Busca notas de prensa por especialidad médica o enfermedad.



Ver todas

Archivo  

Busca notas de prensa por su fecha de edición.

  Selecciona el año


Copyright © 2019, Farmavet, S.L. Todos los derechos reservados.